Investor information

Starting october 19- 2016 MediRox main owner Ahead Global LDT initiated the process to buy 100 percent of MediRox and remove the company from listing on Aktietorget, and since December 21 the company is no longer publicly traded.

The formal  process is expected to commence during 2017. Questions regarding the process is best placed by email on below contact information. 

Our board

The MediRox Board of Director’s work encompasses everything from defining overall strategic planning to business planning, organisational development, product portfolio strategy and performance management.

Peter Schmid

The chairman of the Board Industrial advisor, board member since August, 2011

Tomas L. Lindahl

Board member Professor and Senior Physician, board member since August, 2014

Elvar Theodorsson

Board member Professor and Senior Physician, Founder of the private enterprise BioData since 1985, board member since April, 2013

Bill Tunbrant

Board member CEO of his own company, board member since August, 2014

 

Company background

MedRox was founded in 1998 out of a merger between the Global Haemostasis Institute, a haemostasis research company incubated at the haemostasis laboratory at Linköping University Hospital, and two Swedish national distributors of laboratory equipment. Originally listed in NGM and at Aktietorget, it was bought up by Ahead Global LTD 2016 and unlisted. Ahead globals vision is to further develop MediRox and expand the business world wide.